59 results about "Drugs types" patented technology

A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. The pharmaceutical species is characterized by bioavailability of 30% or less and a molecular weight in the range of 100-1000 Daltons. The composition is characterized further in that the pharmaceutical species is not acyclovir, ganciclovir, BRL44385, or penciclovir. Also described is an inventive method of delivering a pharmaceutical species to an individual including the step of orally administering an inventive prodrug to an individual. In one embodiment the prodrug includes a pharmaceutical species characterized by bioavailability of 30% or less, wherein the pharmaceutical species has a molecular weight in the range of 100-1000 Daltons. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield the pharmaceutical species, such that the pharmaceutical species is delivered to the individual.

The invention belongs to the retail field combining online and offline functions and provides a drug purchasing system combining online and offline functions. The system comprises a platform server, a user terminal, a seller terminal, a delivery terminal, a payment terminal and a remote database and is characterized in that the platform server comprises a drug purchasing list acquisition module used for acquiring drug purchasing lists, a drug type judgment module used of judging the type of drug, a drug purchasing list issuing module used for sending the drug purchasing lists to sellers, a purchasing mode selection module used for acquiring purchasing modes of users, an optimal seller selection module used for selecting an optimal seller in different purchasing modes and a drug checking module used for checking drug information. According to the invention, correct sources of prescription drug lists of purchased drugs are ensured; the drugs are checked, so it is ensured that users can buy true drugs; through delivery of drones, the burning need for drugs of users in emergent conditions is met; and quick and timely services are provided for the users.

A preparation method of a multistage drug release carrier compounded by gelatin microspheres and calcium phosphate cement takes plant oil as continuous phase, disperses the aqueous solution of gelatin in the plant oil to form emulsion and obtains the gelatin microspheres of different grain diameters by controlling the temperature and stirring time of the plant oil; corresponding substances is weighed according to the mass rate (5-20): (95-80) of the gelatin microspheres to the calcium phosphate cement powder, compound powders are obtained after uniform mixing and formulates compound powder sizing agent is prepared by blending NaH2PO4 with the mass percent concentration being 0.8 percent with the compound powder under room temperature for 60-90s; and the blended sizing agent is filled into a mold to be solidified for 1-2h under the conditions of constant temperature of 37 DEG C and 100 percent humidity and finally the compound carrier is obtained. The gelatin microspheres and the bone cement are compounded to construct the drug release compound carrier and encapsulated drug types are designed according to the difference of degradation rates of the gelatin microspheres, so as to realize the timed and quantitative release of different drugs, and simultaneously, as a bone repair support, the drug release carrier can finally substitute a calcium phosphate cement carrier support.

When drugs are prepared according to drug preparation order sheets printed by drug preparation order printers, it is desired to freely set the relation with the printers by setting data without directly connected and fixed to a control program of a control unit of a drug preparation order system so as to cope with e.g. relocations of drug preparation tables. As the drug preparation instruction system, a control unit and a plurality of drug preparation order printers are provided. In the data storage portion of the control unit, data showing the relation between drugs and drug types are stored. By reading drug type codes from inputted drug data, and by reading printer numbers corresponding to the respective drug type codes from a printer setting portion in which are stored data showing the relation between drug type codes and printer numbers, drug data are printed individually by the printers of the set numbers.

The invention provides a method for synchronous detection of multiple residual drugs in a water environment, and belongs to the technical field of pollutant enrichment detection in a water environment. The residual drugs include antibiotics, anti-inflammatory analgesics and antihypertensive drugs, etc., and the synchronous detection method includes the following steps: (1) water sample pretreatment: filter to remove suspended matter, adjust the pH value of the water sample; (2) solidify Phase extraction: use HLB solid-phase extraction column to enrich the target drug; (3) blow nitrogen to nearly dry, dilute to 1mL and vortex for testing; (4) use LC-MS/MS for detection on the machine. The synchronous detection method of the present invention can simultaneously detect 32 pharmaceutical pollutants in the water body by one-time sample injection, and the method has the advantages of high accuracy and sensitivity and low detection limit; meanwhile, the method is environmentally friendly and easy to operate.

It is determined whether the type of drug inserted into a packaging machine is correct, on the basis of the dispensing information of the drug to be packaged and the drug type information of the drug to be inserted into the packaging machine. Number-by-appearance information indicating the number of drugs for each outward appearance which are packaged in each packet is acquired. The image of each drug corresponding to each dose is captured. The number of drugs for each outward appearance which are packaged in each packet is counted on the basis of the captured image of the drugs. It is determined whether the number of drugs for each outward appearance is correct, on the basis of the number-by-appearance information and the counting result of the number-by-appearance counting unit. It is determined whether the occurrence or non-occurrence of a mix-up of the drugs can be determined, on the basis of at least the dispensing information of the drugs to be packaged and the drug type information of the drugs inserted into the packaging machine. It is determined whether the drugs packaged in each packet are correct.

Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.

The invention discloses a method for predicating the embryotoxicity of non-steroidal anti-inflammatory drug type novel pollutants on an early-phase life stage of zebra fish. The method comprises the following steps: exposing zebra fish embryos in the non-steroidal anti-inflammatory drug type novel pollutants which have equal logarithm space concentrations; recording the death rate and the aberration rate of the zebra fish embryos 7 days after exposing; and calculating by using SPSS software to obtain corresponding LC50 and teratogenetic EC50, which are used for evaluating the toxicity of the non-steroidal anti-inflammatory drug type novel pollutants. With the adoption of the method, the toxicity feature and the toxicity level of the non-steroidal anti-inflammatory drug type novel pollutants are subjected to an analytical test and quantitative description; and meanwhile, the method also can be used as an index for monitoring and evaluating the wastewater biological toxicity of non-steroidal anti-inflammatory drugs, and reference is provided for risk predication and evaluation of the potential biological toxicity of the pollutants in a water body.

The invention discloses an intelligent classified storage management system for medicines, comprising a storage space partitioning module, a medicines sales statistics module, a storage path module, amedicines storage module, a storage space detection module, a cloud server and a display terminal; the storage space partitioning module comprises a storage space partitioning module, a medicines sales statistics module, a storage path module, a medicines storage module, a storage space detection module, a cloud server and a display terminal. The storage space partition module is connected with the drug sales statistics module, and the cloud server is connected with the storage space partition module, the drug sales statistics module, the storage path module, the storage space detection module, the drug warehousing module and the display terminal. The invention can partition the storage space of each drug under each drug type, the rationality of storage space is improved, The invention can reasonably allocate the storage space between each storage sub-unit, meet the storage demand, and judge whether the transportation path of each drug stored in each storage sub-unit is correct, thusimproving the judgment of the correctness of the drug storage path, realizing the intelligent classification storage of drugs, improving the storage efficiency and accuracy, and facilitating the management of drugs.

Disclosed is a new application of a bisbenzylisoquinoline derivative shown in formula (I) in the specification or pharmaceutically acceptable salt thereof. The application is an application of the bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof in preparing medicines or health care products for curing depression and easing depression symptom. The bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof can be taken as an effective component to prepare a drug type of any form. A result of an animal experiment shows that, the bisbenzylisoquinoline compound shown in formula (I) or the pharmaceutically acceptable salt thereof can obviously shorten immobility time of a mouse in a forced swimming test and immobility time of the mouse in a tail suspending test, which shows an anti-depression function. The present invention is applicable to various types of depression.

The invention provides a drug network pharmacology intelligent and quantitative analysis method and system based on a network target original theory, wherein the method and system are used for measuring the overall effect of intervening a disease biological network by drugs (including various drug types such as Chinese and western drugs). The method can integrate qualitative and/or quantitative biological information related to diseases and drugs, takes the disease biological network as a target and realizes effect measurement of drug intervention on the disease biological network from the system and overall perspective, and reveals the overall action mechanism of the drugs. The method provides a qualitative and quantitative selectable measurement mode, measures the drug intervention network effect by adopting biological function multi-scale qualitative analysis and/or time-space multi-dimensional quantitative analysis, and provides a new key technique for breaking through the limitation of a traditional experience-based or single-target-based drug research mode, understanding a drug network regulation mechanism, and quickly and intelligently discovering pharmacodynamic substances, action mechanisms, curative effect objective indexes and clinical indications and the like.

Systems and methods for prescription drug packaging are described. In some embodiments, a determination that a member of a pharmacy benefit plan has had a plurality of prescription drugs that have previously been filled is made. An adjudication request for a prescription drug prescribed for the member is received. The adjudication request is based on a fulfillment request to fill the prescription drug. A determination that a blister packaging criterion has been met may be made based on a drug type of the prescription drug and a determination that the member has had the plurality of prescription drugs that have previously been filled. A blister fill instruction is transmitted based on receipt of the adjudication request and a determination that the blister packaging criterion has been met, wherein the blister fill instruction reflects that a pharmacy is to fill the prescription drug utilizing blister packaging. Additional methods and systems are disclosed.

The invention relates to an embedded type graded drug release three-dimensional rack and a preparation method of the rack. A rack inner-layer shaped body with high porosity is wrapped by a rack outer-layer shaped body with low porosity to form an embedded bi-layer structural rack. The classes of drugs carried by the inner layer and the outer layer of the rack are different. The graded distribution of drug classes and the graded distribution of rack microstructures are realized in the same rack, thereby obtaining the embedded two-graded drug release artificial rack. The preparation process of the multi-graded drug release rack comprises the three steps, namely, (1) freeze-forming of the drug carrying rack inner-layer shaped body; (2) freeze-forming of the drug carrying rack outer-layer wrapping shaped body; and (3) drying the embedded rack in a low temperature and vacuum. In the embedded multi-layer rack prepared in the invention, the content of calcium phosphate and the drug classes in a composite slurry used in each layer of the rack are respectively different; the degradation rate of the rack is related to the solid content of solid phase; as the solid content of the slurry is different, the degradation rate of the prepared rack is different; and the release rate of the drug is influenced by the rack degradation.

The invention discloses an intelligent management cabinet for poisonous and anesthetic drugs, which comprises a cabinet body, a control assembly and a plurality of drug storage cells, and is characterized in that each drug storage cell is controlled to be opened and locked through an electromagnetic lock; the control assembly comprises a touch screen computer and an identity recognizer, and the identity recognizer and the electromagnetic lock are both connected with the touch screen computer; the touch screen computer can achieve the following steps that when identity information input by an anesthesia nurse is detected, the identity information is verified, and the corresponding drug storage cells are opened after the identity information passes verification; after the drug is replaced, the taking permission of each drug storage cell input by the anesthesia nurse is obtained; when the identity information input by an anesthetist is detected, the identity information is verified, and the operation room number, the drug box and drug types and the base number corresponding to the authority of the anesthetist are displayed after the verification is passed; and after confirmation operation of the anesthetist is received, the corresponding drug storage cells are opened. The system achieves the intelligent management of toxic and numb drugs, and improves the work efficiency.

A platform configured to predict type or family of an unknown drug candidate compound, the platform including: a living cell or a tissue; a detector that measures an indicator of a cellular response by the living cell or tissue upon exposure to the unknown drug candidate compound; a memory configured to store data related to the indicator of the cellular response detected by the detector from a library of drug types and/or families; and one or more processing unit(s) configured to: process the data related to the indicator of the cellular response of the living cell or tissue upon exposure to the unknown drug candidate compound, and compare cellular response data from the library of drug types and/or families, so that a drug type and/or a drug family and/or a mechanism of action of the unknown drug candidate compound can be predicted on the basis of a similarity between the detected cellular response data of the unknown drug candidate compound and the cellular response data of the library of drug types and/or families. Also disclosed are methods of screening an unknown drug, including: comparing the data measured from a test cell to corresponding cellular response data in a library of known drug types, and determining a relationship between the unknown drug and a known drug type or a known drug family to predict the type or family of the unknown drug.

The invention discloses an application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis and belongs to the field of biomedicine. Screened drug types comprise: bone morphogenetic protein-4 formation inhibitor, bone morphogenetic protein-4 antagonistic, bone morphogenetic protein-4 receptor antagonists and bone morphogenetic protein-4 downstream signal antagonistic. The invention also relates to an application of the drugs in preparation of medicines for resisting cardiac hypertrophy, heart failure and arrhythmia. Researches have found that bone morphogenetic protein-4 can induce myocardial hypertrophy, apoptosis and cardiac fibroblast collagen secretion increase, lead to occurrence of cardiac hypertrophy, heart failure and arrhythmia. However, drugs for antagonism of bone morphogenetic protein-4 and its cell signaling pathway can be used to inhibit occurrence of cardiac hypertrophy, inhibit cardiac fibrosis and minimize occurrence of cardiac cell death and arrhythmia. The invention provides a theoretical basis for realizing high-flux medicine screening, and is of practical guiding significance.

The invention relates to the technical field of a traditional Chinese medicine decoction piece, and particularly relates to a traditional Chinese medicine decoction piece single machine. Discharge hoppers of the traditional Chinese medicine decoction piece single machine are arranged on a weighing sensor and a weighing rechecking sensor, thus drug of the discharge hoppers can be weighted twice, and the weighing accuracy is ensured; the opening angle of a blocking door in the device can be adjusted according to the drug type and weight; when more drugs are required, the opening angle of the block door is big; when the drug weight approaches to the setting weight, the opening angle of the block door is small, thus the drug can rapidly reach the setting weight. Use of the traditional Chinese medicine decoction piece single machine can effectively reduce the labor intensity when a worker takes drugs, and reduce the bias of artificially weighing drugs, thus the drug weighing is more exact and faster. Besides, the traditional Chinese medicine decoction piece single machine is reasonable in structure design, convenient to use and repair, and suitable for popularizing and use.

This disclosure relates to a system and a method for automated recognition of drugs. This disclosure also relates to a system for automated recognition of drugs comprising a hyper-spectral imaging system. This disclosure also relates to a hyper-spectral imaging system configured to automatically recognize drugs by using a neural network. This disclosure relates to training the neural network to identify a drug type (e.g., the name of the drug) based on an image (e.g., normal visible image and/or hyperspectral image) of the drug.

The invention relates to an automatic drug selling system based on cloud service. The system comprises automatic drug selling machines, a cloud service platform and a mobile phone user side. The cloud service platform obtains position, drug stock and drug type information of each automatic drug selling machine; the cloud service platform transmits the position, drug stock and drug type information of each automatic drug selling machine to a mobile phone APP; and a user can search the information of each drug selling machine through the mobile phone APP, selects the closest drug selling machine, selects required type and quantity of drugs through the mobile phone APP and carries out on-line payment through the mobile phone APP. According to the automatic drug selling system based on cloud service, automatic drug selling system technology based on cloud service is applied to automatic drug selling equipment, thereby facilitating people's lives greatly, and making drug purchase more convenient and quicker.

The invention provides a medicine dispensing method and device for a medicine dispensing system, and the method comprises the following steps: obtaining a first medicine type from a prescription, themedicine dispensing quantity corresponding to the first medicine type being greater than or equal to 1, and the prescription comprising a plurality of medicine types and the medicine dispensing quantity corresponding to each medicine type; based on the first medicine type, controlling a medicine dispensing system to send out the to-be-verified medicine from a medicine outlet, controlling a camerato shoot a medicine box image of the to-be-verified medicine, and obtaining a second medicine type corresponding to the to-be-verified medicine from the medicine box image; and when it is determined that the first drug type and the second drug type are the same, subtracting one from the dispensing quantity corresponding to the first drug type in the prescription. In the medicine dispensing method,the system checks each box of dispensed prescription medicines one by one, so that the error probability of medicine type identification can be greatly reduced.

The invention discloses a dynamic performance evaluation device for a water purifying agent used for oily sewage. According to the flow direction of the oily sewage, the device sequentially includes an oily sewage flow rate regulating unit, a dosing control unit, a variable oil-water separation unit, a simulated sedimentation unit, and a sewage storage and discharge control unit. Under the condition that actual operating working conditions of the oily wastewater in different oil fields can be simulated, the device is a dynamic evaluation device by changing different water quality, different flow rates, different drug types, different dosing concentration, different dosing positions, different oil-water separation processes, different water discharge heights to perform comprehensive measurement on the performance of the water purifying agent used for the oily sewage.

According to the drug inventory cardinal number adjusting system and the drug inventory cardinal number adjusting method, the types and the number of the drugs called into the target drug library are determined according to different target drug library types and different drug types (standing drugs, seasonal drugs and special drugs), dynamic adjustment of the drug library inventory is achieved, the hospital drug management efficiency is improved, timely supply of drugs is guaranteed, the drug turnover rate is increased, drug inventory backlog is reduced, and the hospital drug storage cost is reduced.

The invention relates to hemostatic and anti-infection pharmaceutical composition. The pharmaceutical composition comprises an effective component and medically acceptable auxiliaries, and is characterized in that the effective component is prepared from raw materials in percentage by weight as follows: 65%-85% of tobacco and 15%-35% of rhizoma bletillae. The pharmaceutical composition not only has remarkable hemostatic and anti-infection effects, but also contains fewer drug types and is stable in quality.